A股異動丨康恩貝午後漲近4%正對工業大麻進行全產業鏈佈局
格隆匯8月15日丨康恩貝(600572.SH)午後漲幅擴大,現報6.27元,漲3.98%,暫成交2.67億元,最新總市值167.24億元。康恩貝集團董事長鬍季強在“上市公司工業大麻論壇”上表示,康恩貝目前在做的,是對工業大麻的基礎性研究和全產業鏈佈局。集團首先推進的是工業大麻前端部分即種植與提取。集團分別在雲南曲靖、文山和瀘西縣種植了2.4萬畝工業大麻,還在瀘西和曲靖改造了兩個植物提取廠,準備了約6000噸花葉的提取加工產能(目前正在申請等待加工許可證)。並稱集團還與黑龍江某企業達成了戰略合作,將協同開發國際CBD市場。第一階段的目標是要成為國內乃至全球最大的CBD提取物供應商。(行情來源:富途證券)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.